Zydus Cadila vaccine: ZyCoV-D LAUNCH in September! PRICE not finalised, aims to produce 5 cr doses by January 2022, says MD Sharvil Patel

Zydus Cadila's ZyCoV-D vaccine was granted approval for emergency use from the Drug Controller General of India (DCGI) on August 20, 2021. It is the world’s first and India’s indigenously developed DNA based vaccine for COVID-19.  The vaccine will be administered in 3-dose and work on even Children and adults of age 12 years and above. 

See Zee Business Live TV Streaming Below:

Talking about this vaccine, Sharvil Patel, Managing Director, Zydus Cadila, on Saturday said there was no adverse case reported during the trail of vaccine. " The vaccine was seen stable in 2 to 8 degrees. It was found that efficacy was good while kept at 25 degrees. The company plans to manufacture 10 to 12 crore vaccine dose in one year and launch is likle to start from September. There has not been any decision made as far as pricing of the vaccine is concerned," said Patel 

Here are the highlights of Zydus Cadila's MD media briefing: 

• Sharvil Patel said the trail was conducted with the help of 1,000 ventilators.  
• The vaccine will be administered without needle through thermo jet 
• The process of this vaccine will complete in 2 months duration.  
• No decision regarding pricing has been made, while the vaccine is expected to hit the market by September. 
• Both Government and private organisations will be provided vaccine, however, a big chunk will be given to central government, Patel said. 
• We aim to produce 3 to 5 crore vaccine doses by January next year. 
• We are also in talk with some foreign companies related to technology transfer 
• It is expected that full data of phase 3 trail will and publishing of the report may take 4 to 6 months 
• We have been granted approval based on phase 1, phase 2 and phase 3 efficacy data  
• We are targeting a dose of 1 core by the end of October and 5 crore by January. 
• The vaccine will be effective on anyone above 12 years old.